The results clearly showed that 276 ESCC patients were divided into four groups as follows: TP53 mutation/p53 high expression (85/276, 30.8%), TP53 mutation/p53 low expression (127/276, 46.0%), TP53 wild-type/p53 high expression (23/276, 8.3%), TP53 wild-type/p53 low expression (41/276, 14.9%) (Table 5). Here, TP53 is linked to esophageal squamous cell carcinoma.